First FDA Approval of dual anti-HER2 regimen: Pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer

Clinical Cancer Research

Volumn 19, Issue 18, 2013, Pages 4911-4916

  Blumenthal, Gideon M ^a   Scher, Nancy S ^a   Cortazar, Patricia ^a   Chattopadhyay, Somesh ^a   Tang, Shenghui ^a   Song, Pengfei ^a   Liu, Qi ^a   Ringgold, Kimberly ^a   Pilaro, Anne M ^a   Tilley, Amy ^a   King, Kathryn E ^a   Graham, Laurie ^a   Rellahan, Barbara L ^a   Weinberg, Wendy C ^a   Chi, Bo ^a   Thomas, Colleen ^a   Hughes, Patricia ^a   Ibrahim, Amna ^a   Justice, Robert ^a   Pazdur, Richard ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; LETROZOLE; PACLITAXEL; PERTUZUMAB; PLACEBO; TRASTUZUMAB;

ALOPECIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CARDIOTOXICITY; CONSTIPATION; DIARRHEA; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MANUFACTURE; DRUG POTENTIATION; DRY SKIN; FATIGUE; FEBRILE NEUTROPENIA; FETOTOXICITY; FOOD AND DRUG ADMINISTRATION; HUMAN; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; MUCOSA INFLAMMATION; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QT INTERVAL; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RECOMBINANT DNA TECHNOLOGY; SIDE EFFECT; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DOUBLE-BLIND METHOD; DRUG APPROVAL; FEMALE; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, ERBB-2; TAXOIDS; TREATMENT OUTCOME; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84884564646     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-1212     Document Type: Article

References (16)

1. Breast Cancer Facts & Figures, American Cancer Society, 2011-2012. Available from: http://www.cancer.org/research/cancerfacts figures/ breastcancerfactsfigures/breast-cancer-facts-and-figures-2011-2012.
2. Perez EA, Romond EH, Suman VJ, Jeong JH, Davidson NE, Geyer CE Jr, et al. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol 2011;29:3366-73.
3. Gianni L, Dafni U, Gelber RD, Azambuja E, Muehlbauer S, Goldhirsch A, et al. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomized controlled trial. Lancet Oncol 2011;12:236-44
4. Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 2011;365:1273-83.
5. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92.
6. Capelan M, Pugliano L, De Azambuja E, Bozovic I, Saini KS, Sotiriou C, et al. Pertuzumab: new hope for patients with HER2-positive breast cancer. Ann Oncol 2013;24:273-82.
7. Hudis CA. Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med 2007;357:39-51.
8. De Hoon JP, Veeck J, Vriens BE, Calon TG, van Engeland M, Tjan-Heijnen VC. Taxane resistance in breast cancer: a closed HER2 circuit? Biochim Biophys Acta 2012;1825:197-206.
9. U. S. Food and Drug Administration. Drug approval package, Perjeta (pertuzumab) injection. Available from: www.accessdata.fda.gov/drugsatfda-docs/ nda/2012/125409Orig1s000TOC.cfm
10. Baselga J, Cortés J, Kim SB, Im SA, Hegg R, Im YH, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. NEngl J Med 2012;366:109-19.
11. Gianni L, Pienkowski Y, Im YH, Roman L, Tseng LM, Liu MC, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomized multicentre, open-label, phase II trial. Lancet Oncol 2012;13:25-32.
12. Cortés J, Fumoleau P, Bianchi GV, Petrella TM, Gelmon K, Pivot X, et al. Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2012;30:1594-600.
13. Swain SM, Kim SB, Cortés J, Ro J, Semiglazov V, Campone M, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomized, double-blind, placebo-controlled, phase III study. Lancet Oncol 2013;14:461-71.
14. ClinicalTrials.gov Identifier: NCT01491737. A study of pertuzumab with trastuzumab plus an aromatase inhibitor in patients with hormone receptor-positive, metastatic, HER2-positive breast cancer. Available from: http://clinicaltrials.gov/show/NCT01491737.
15. Portera CC, Walshe JM, Rosing DR, Denduluri N, Berman AW, Vatas U, et al. Cardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. Clin Cancer Res 2008;14:2710-6.
16. ClinicalTrials.gov Identifier: NCT01358877. A study of pertuzumab in addition to chemotherapy and herceptin (trastuzumab) as adjuvant therapy in patients with HER2-positive primary breast cancer. Available from: http://clinicaltrials.gov/show/NCT01358877.